Q2 2025

Filed Aug 4, 2025 · 10-Q · 35 days after period end · 0000950170-25-101985

Q2 2025 · 10-Q

Revenue

$37.96M

+984.5% vs Q2 2024

Net Income

-$71.85M

N/M vs Q2 2024

EPS Diluted

-$0.83

N/M vs Q2 2024

Operating Income-$69,353,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$37.96M	$3.50M	$0.00	—
Net Income	-$71.85M	-$68.06M	-$44.62M	-$37.57M
EPS Diluted	-$0.83	-$0.80	-$0.64	-$0.62

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR